High serum concentrations of Sialyl Lewisx predict multilevel N2 disease in non-small-cell lung cancer

Annals of Surgical Oncology

Volumn 13, Issue 7, 2006, Pages 1010-1018

  Mizuguchi, Shinjiro ^a,b   Inoue, Kiyotoshi ^a   Iwata, Takashi ^a   Nishida, Tatsuya ^a   Izumi, Nobuhiro ^a   Tsukioka, Takuma ^a   Nishiyama, Noritoshi ^a   Uenishi, Takahiro ^a   Suehiro, Shigefumi ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Osaka Prefecture University   (Japan)

Author keywords

Lung cancer; Mediastinal lymph node; Multilevel; N2; Sialyl Lewisx

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19 FRAGMENT; SIALYL LEWIS X ANTIGEN; SQUAMOUS CELL CARCINOMA ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER SIZE; CANCER SURVIVAL; DIAGNOSTIC VALUE; FEMALE; HUMAN; KAPLAN MEIER METHOD; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG RESECTION; LUNG SQUAMOUS CELL CARCINOMA; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM LYMPH NODE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; RADIOIMMUNOASSAY; SENSITIVITY AND SPECIFICITY; SERUM; STATISTICAL ANALYSIS; SURVIVAL RATE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; LEWIS BLOOD-GROUP SYSTEM; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; OLIGOSACCHARIDES; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 33745280951     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/ASO.2006.05.018     Document Type: Article

References (55)

1. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997; 111:1710-7.
2. Vansteenkiste JF, De Leyn PR, Deneffe GJ, et al. Survival and prognostic factors in resected N2 non-small cell lung cancer: a study of 140 cases. Leuven Lung Cancer Group. Ann Thorac Surg 1997; 63:1441-50.
3. Okada M, Tsubota N, Yoshimura M, Miyamoto Y, Matsuoka H. Prognosis of completely resected pN2 non-small cell lung carcinomas: what is the significant node that affects survival? J Thorac Cardiovasc Surg 1999; 118:270-5.
4. Riquet M, Manac'h D, Le Pimpec-Barthes F, Dujon A, Chehab A. Prognostic significance of surgical-pathologic N1 disease in non-small cell carcinoma of the lung. Ann Thorac Surg 1999; 67:1572-6.
5. Robinson LA, Wagner H Jr, Ruckdeschel JC. Treatment of stage IUA non-small cell lung cancer. Chest 2003; 123:202-20.
6. Ichinose Y, Kato H, Koike T, et al. Overall survival and local recurrence of 406 completely resected stage IIIa-N2 non-small cell lung cancer patients: questionnaire survey of the Japan Clinical Oncology Group to plan for clinical trials. Lung Cancer 2001; 34:29-36.
7. Tanaka F, Yanagihara K, Otake Y, et al. Prognostic factors in resected pathologic (p-) stage IIIA-N2, non-small-cell lung cancer. Ann Surg Oncol 2004; 11:612-8.
8. Sawabata N, Keller SM, Matsumura A, et al. The impact of residual multi-level N2 disease after induction therapy for non-small cell lung cancer. Lung Cancer 2003; 42:69-77.
9. Ueda K, Kaneda Y, Sakano H, et al. Independent predictive value of the overall number of metastatic N1 and N2 stations in lung cancer. Jpn J Thorac Cardiovasc Surg 2003; 51:297-301.
10. De Leyn P, Vansteenkiste J, Deneffe G, Van Raemdonck D, Coosemans W, Lerut T. Result of induction chemotherapy followed by surgery in patients with stage IIIA N2 NSCLC: importance of pre-treatment mediastinoscopy. Eur J Cardiothorac Surg 1999; 15:608-14.
11. Friedel G, Hruska D, Budach W, et al. Neoadjuvant chemoradiotherapy of stage III non-small-cell lung cancer. Lung Cancer 2000; 30:175-85.
12. Trodella L, Granone P, Valente S, et al. Neoadjuvant concurrent radiochemotherapy in locally advanced (IIIA-IIIB) non-small-cell lung cancer: long-term results according to downstaging. Ann Oncol 2004; 15:389-98.
13. Fernando HC, Goldstraw P. The accuracy of clinical evaluative intrathoracic staging in lung cancer as assessed by post-surgical pathologic staging. Cancer 1990; 65:2503-6.
14. Goldstraw P, Mannam GC, Kaplan DK, Michail P. Surgical management of non-small-cell lung cancer with ipsilateral mediastinal node metastasis (N2 disease). J Thorac Cardiovasc Surg 1994; 107:19-27.
15. Moro D, Villemain D, Vuillez JP, Delord CA, Brambilla C. CEA, CYFRA21-1 and SCC in non-small cell lung cancer. Lung Cancer 1995; 13:169-76.
16. Pujol JL, Molinier O, Ebert W, et al. CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patients. Br J Cancer 2004; 90:2097-105.
17. Stieber P, Hasholzner U, Bodenmuller H, et al. CYFRA 21-1. A new marker in lung cancer. Cancer 1993; 72:707-13.
18. Sugama Y, Kitamura S, Kawai T, et al. Clinical usefulness of CYFRA assay in diagnosing lung cancer: measurement of serum cytokeratin fragment. Jpn J Cancer Res 1994; 85:1178-84.
19. Brechot JM, Chevret S, Nataf J, et al. Diagnostic and prognostic value of Cyfra 21-1 compared with other tumour markers in patients with non-small cell lung cancer: a prospective study of 116 patients. Eur J Cancer 1997; 33:385-91.
20. Takamochi K, Nagai K, Suzuki K, Yoshida J, Ohde Y, Nishiwaki Y. Clinical predictors of N2 disease in non-small cell lung cancer. Chest 2000; 117:1577-82.
21. Ando S, Kimura H, Iwai N, Kakizawa K, Shima M, Ando M. The significance of tumour markers as an indication for mediastinoscopy in non-small cell lung cancer. Respirology 2003; 8:163-7.
22. Takada M, Masuda N, Matsuura E, et al. Measurement of cytokeratin 19 fragments as a marker of lung cancer by CY-FRA 21-1 enzyme immunoassay. Br J Cancer 1995; 71:160-5.
23. Bevilacqua MP, Pober JS, Mendrick DL, Cotran RS, Gimbrone MA Jr. Identification of an inducible endothelial-leukocyte adhesion molecule. Proc Natl Acad Sci USA 1987; 84:9238-42.
24. Lowe JB, Stoolman LM, Nair RP, Larsen RD, Berhend TL, Marks RM. ELAM-1-dependent cell adhesion to vascular endothelium determined by a transfected human fucosyl-transferase cDNA. Cell 1990; 63:475-84.
25. Phillips ML, Nudelman E, Gaeta FC, et al. ELAM-1 mediates cell adhesion by recognition of a carbohydrate ligand, sialyl-Lex. Science 1990; 250:1130-2.
26. Walz G, Aruffo A, Kolanus W, Bevilacqua M, Seed B. Recognition by ELAM-1 of the sialyl-Lex determinant on myeloid and tumor cells. Science 1990; 250:1132-5.
27. Takada A, Ohmori K, Takahashi N, et al. Adhesion of human cancer cells to vascular endothelium mediated by a carbohydrate antigen, sialyl Lewis A. Biochem Biophys Res Commun 1991; 179:713-9.
28. Berg EL, Magnani J, Warnock RA, Robinson MK, Butcher EC. Comparison of L-selectin and E-selectin ligand specificities: the L-selectin can bind the E-selectin ligands sialyl Le(x) and sialyl Le(a). Biochem Biophys Res Commun 1992; 184:1048-55.
29. Bresalier RS, Ho SB, Schoeppner HL, et al. Enhanced sialylation of mucin-associated carbohydrate structures in human colon cancer metastasis. Gastroenterology 1996; 110:1354-67.
30. Imada T, Rino Y, Takahashi M, et al. Serum CA 19-9, SLX, STN and CEA levels of the peripheral and the draining venous blood in gastric cancer. Hepatogastroenterology 1999; 46:2086-90.
31. Nakagoe T, Sawai T, Tsuji T, et al. Predictive factors for preoperative serum levels of sialy Lewis(x), sialyl Lewis(a) and sialyl Tn antigens in gastric cancer patients. Anticancer Res 2002; 22:451-8.
32. Ikeda Y, Mori M, Kajiyama K, Haraguchi Y, Sasaki O, Sugimachi K. Immunohistochemical expression of sialyl Tn, sialyl Lewis a, sialyl Lewis a-b-, and sialyl Lewis x in primary tumor and metastatic lymph nodes in human gastric cancer. J Surg Oncol 1996; 62:171-6.
33. Nakagoe T, Kusano H, Hirota M, et al. Serological and immunohistochemical studies on sialylated carbohydrate antigens in colorectal carcinoma. Gastroenterol Jpn 1991; 26:303-11.
34. Nakagoe T, Fukushima K, Hirota M, et al. Immunohistochemical expression of sialyl Lex antigen in relation to survival of patients with colorectal carcinoma. Cancer 1993; 72:2323-30.
35. Tanaka K, Togo S, Nanko M, et al. Sialyl Lewis X expression in vascular permeating lesions as a factor for predicting colorectal cancer metastasis. Hepatogastroenterology 1999; 46:875-82.
36. Yamaguchi A, Goi T, Seki K, et al. Clinical significance of combined immunohistochemical detection of CD44v and sialyl LeX expression for colorectal cancer patients undergoing curative resection. Oncology 1998; 55:400-3.
37. Ogawa J, Tsurumi T, Yamada S, Koide S, Shohtsu A. Blood vessel invasion and expression of sialyl Lewisx and proliferating cell nuclear antigen in stage I non-small cell lung cancer. Relation to postoperative recurrence. Cancer 1994; 73:1177-83.
38. Tsumatori G, Ozeki Y, Takagi K, Ogata T, Tanaka S. Relation between the serum E-selectin level and the survival rate of patients with resected non-small cell lung cancers. Jpn J Cancer Res 1999; 90:301-7.
39. Mukae H, Hirota M, Kohno S, et al. Elevation of tumor-associated carbohydrate antigens in patients with diffuse panbronchiolitis. Am Rev Respir Dis 1993; 148:744-51.
40. Yokoyama A, Kohno N, Kondo K, et al. Comparative evaluation of sialylated carbohydrate antigens, KL-6, CA19-9 and SLX as serum markers for interstitial pneumonia. Respirology 1998; 3:199-202.
41. World Health Organization. Histological typing of lung and pleural tumours. In: Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E, (eds). Collaboration with Pathologists in 14 Countries. 3rd ed. Geneva: World Heath Organization, 1999.
42. Naruke T, Suemasu K, Ishikawa S. Surgical treatment for lung cancer with metastasis to mediastinal lymph nodes. J Thorac Cardiovasc Surg 1976; 71:279-85.
43. Martini N, Flehinger BJ. The role of surgery in N2 lung cancer. Surg Clin North Am 1987; 67:1037-49.
44. Oyama T, Kawamoto T, Matsuno K, et al. A case-case study comparing the usefulness of serum trace elements (Cu, Zn and Se) and tumor markers (CEA, SCC and SLX) in non-small cell lung cancer patients. Anticancer Res 2003; 23:605-12.
45. Nishida K, Yamamoto H, Ohtsuki T, et al. Elevated tissue concentrations of sialyl Lex-i in cancerous tissues compared with those in noncancerous tissues of various organs. Cancer 1991; 68:111-7.
46. Kawai T, Suzuki M, Kase K, Ozeki Y. Expression of carbohydrate antigens in human pulmonary adenocarcinoma. Cancer 1993; 72:1581-7.
47. Stetler-Stevenson WG, Aznavoorian S, Liotta LA. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol 1993; 9:541-73.
48. Folkman J. Tumor angiogenesis. Adv Cancer Res 1985; 43:175-203.
49. Volm M, Koomagi R, Mattern J. PD-ECGF, bFGF, and VEGF expression in non-small cell lung carcinomas and their association with lymph node metastasis. Anticancer Res 1999; 19:651-5.
50. O'Byrne KJ, Koukourakis MI, Giatromanolaki A, et al. Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer. Br J Cancer 2000; 82:1427-32.
51. Miyoshi T, Kondo K, Hino N, Uyama T, Monden Y. The expression of the CD44 variant exon 6 is associated with lymph node metastasis in non-small cell lung cancer. Clin Cancer Res 1997; 3:1289-97.
52. Tran TA, Kallakury BV, Sheehan CE, Ross JS. Expression of CD44 standard form and variant isoforms in non-small cell lung carcinomas. Hum Pathol 1997; 28:809-14.
53. Tokuraku M, Sato H, Murakami S, Okada Y, Watanabe Y, Seiki M. Activation of the precursor of gelatinase A/72 kDa type IV collagenase/MMP-2 in lung carcinomas correlates with the expression of membrane-type matrix metalloproteinase (MT-MMP) and with lymph node metastasis. Int J Cancer 1995; 64:355-9.
54. Sasaki H, Yukiue H, Moiriyama S, et al. Clinical significance of matrix metalloproteinase-7 and Ets-1 gene expression in patients with lung cancer. J Surg Res 2001; 101:242-7.
55. Tamura M, Oda M, Matsumoto I, et al. The combination assay with circulating vascular endothelial growth factor (VEGF)-C, matrix metalloproteinase-9, and VEGF for diagnosing lymph node metastasis in patients with non-small cell lung cancer. Ann Surg Oncol 2004; 11:928-33.